Chem okines are prom ising biom arkers of im m une activation an d inflamm ation, but evidence for chem okine abn orm alities in sch izophrenia and their relationship to clinical factors rem ains inconclusive. We aim ed to understand chemokine-related diagnostic differences and clinical correlates using a comprehensive panel and studying a large, w ell-characterized sam ple of adults w ith and w ithout schizophrenia. We studied 134 outpatients w ith schizoph renia or schizoaffective disorder and 112 healthy com parison ( HC) individuals, 26 to 65 years of age. Clinical m easures w ere obtained, and plasm a levels of 11 chemokines w ere assessed using m ultiplex imm unoassay. Schizophrenia vs. HCdifferences w ere tested for each chem okine, adjusting for age, gender, body m ass index, and current sm oking status. We also exam ined w hether age and gender relationsh ips differed betw een diagnostic groups. Using logistic regression, w e created a Chem okine Index ( CI) and explored its clinical correlates. Levels of m onocyte chem oattractant protein-1 ( MCP-1/CCL2), m acrophage inflam m atory protein-1β (MIP-1β/CCL4), Eotaxin-1 ( CCL11), thym us and activation-regulated chem okine ( TARC/CCL17), and m acrophage-derived chem okine (MDC/CCL22) w ere significantly h igher in person s w ith schizophren ia th an HCs. Group differences in TARC w ere reduced after adjusting for covariates. The CI, a linear com bination of Eotaxin-1 and MDC levels, w as positively associated w ith age, duration of schizoph ren ia, and severity of negative sym ptom s. Levels of chem okin es w ith neuroim m une regulatory effects w ere higher in individuals w ith schizophren ia, particularly in older and chronic patients. Treatm ents aim ed at norm alizing chem okine levels m ight im prove m ental and physical health am ong schizophrenia patients as th ey age.
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Intr oduction
Person s w ith schizophren ia have in creased m orbidity and m ortality rates from m edical illnesses, especially cardiovascular diseases ( Brow n , 1997; Inskip et al., 1998) . Schizophrenia h as been associated w ith imm un e dysfunction an d in flam m ation ( Dickerson et al., 2016) , w h ich m ay con tribute to accelerated aging and greater com orbidity and m ortality ( Kirkp atrick et al., 2008) . The large CATIE study reported higher levels of inflamm atory m arkers (Meyer et al., 2009 ) and elevated coronary heart disease risk in people w ith schizophrenia, especially am ong w om en (Goff et al., 2005) . Autoimm une diseases and chronic inflammatory con dition s occur w ith h igher frequ ency in person s w ith sch izoph ren ia ( Benros et al., 2014b) . In dividuals w ith sch izoph renia reportedly have increased plasm a concentrations of C-reactive protein, interleukin ( IL) -6, IL-6 receptor, tum or necrosis factor-α , and soluble IL-2 recep tor ( Joseph et al., 2015; Lin et al., 1998; Maes et al., 1995; Mondelli et al., 2015; Naudin et al., 1996) . Also, treatm ent w ith non-steroidal anti-inflam m atory cyclooxygenase-2 in hibitors w as show n to reduce psychotic sym ptom s in patients w ith recent-onset psychosis but not chronic psychosis ( Nitta et al., 2013; Rapaport et al., 2005) . Taken togeth er, im m une activation /in flam m ation is associated w ith schizophrenia, but m ore com prehensive investigations are necessary to specify th e nature of im mune alteration s and their clinical correlates.
Chem okin es con stitute a fam ily of sm all ( 7-12 kDA) cytokines and in du ce directed ch em otaxis in n earby respon sive cells. Ch em okin es play an integral role in im m un e function, m ediating leukocyte m igration and trafficking, and inflam m atory responses (Foxm an et al., 1997; Murphy et al., 2000b; Sprin ger, 1994) . Recent studies suggest direct roles of chem okines in the central nervous system (CNS), including neuroen docrine function , neurotransm ission, and neu rodegen eration ( Reaux-Le Goazigo et al., 2013) . Elevated levels of chem okines in the CNS an d blood are observed in several n eu roin flam m atory disorders such as m ultiple sclerosis (Balashov et al., 1999; Sorensen et al., 1999) , as w ell as psychiatric conditions including depression, bipolar disorder, and sch izophren ia (Eyre et al., 2016; Panizzutti et al., 2015; Stuart and Baune, 2014) .
The literature on ch em okine levels in schizoph ren ia is in form ative but has lim itations. Most studies exam ined a relatively sm all num ber of chem okin es in m ale-dom inant sam ples. Th ese in vestigations vary w idely in considerin g potential dem ographic and clin ical correlates in an alyzin g sch izop hren ia-ch em okin e relation sh ip s ( Beum er et al., 2012; Xu et al., 2015) . Monocyte ch em oattractan t protein ( MCP)-1 is the best-studied chem okine, but the findings are equivocal w ith nearly equal num bers of studies showing significantly higher ( Beum er et al., 2012; Dim itrov et al., 2013; Dom enici et al., 2010; Reale et al., 2011; Zakharyan et al., 2012) or similar (Asevedo et al., 2013; Bram billa et al., 2014; Di Nicola et al., 2013; Martinez-Cengotitabengoa et al., 2012; Schw arz et al., 2012; Teixeira et al., 2008) levels betw een schizophrenia patients and healthy com parison subjects ( HCs). There are also inconsistent findings for IL-8 ( Dennison et al., 2012; Di Nicola et al., 2013; Erbagci et al., 2001; Kam inska et al., 2001; Maes et al., 2002; O'Brien et al., 2008; Ram sey et al., 2013; Reale et al., 2011; Zh an g et al., 2002) , Eot axin -1 ( Asevedo et al., 2013; Dom en ici et al., 2010; Pedrin i et al., 2014; Ram sey et al., 2013; Teixeira et al., 2008) , and m acrophage derived chem okine ( MDC; Bram billa et al., 2014; Dim itrov et al., 2013; Dom enici et al., 2010; Ram sey et al., 2013; Schwarz et al., 2012) . Other ch em okines, in cluding m acroph age in flam m atory protein ( MIP) -1α ( Aseved o et al., 2013; Bram billa et al., 2014; Dim itrov et al., 2013; Dom en ici et al., 2010; Nikkila et al., 2002; Sch w arz et al., 2012; Teixeira et al., 2008; Zakharyan et al., 2012) , MIP-1β ( Beum er et al., 2012; Bram billa et al., 2014; Dim itrov et al., 2013; Dom en ici et al., 2010; Schw arz et al., 2012) , and interferon-induced protein-10 ( IP-10; Asevedo et al., 2013; Bram billa et al., 2014; Dim itrov et al., 2013; Teixeira et al., 2008) h ave not been sh ow n to differ betw een people w ith schizoph renia an d HCs. Fin ally, MCP-4 ( Teixeira et al., 2008) , Eotaxin -3 ( Schw arz et al., 2012) , fractalkine ( Dim itrov et al., 2013) , and thym us and activation-regulated chemokine ( TARC) have received little atten tion in schizoph ren ia. Men w ith schizophrenia h ave sh ow n higher chem okine levels ( e.g., IL-8, MCP-1, MDC, MIP-1α , and MIP-1β) than women with schizophrenia in some studies (Beum er et al., 2012; Dom enici et al., 2010; Ramsey et al., 2013) .
We assessed plasm a levels of 11 chem okines in a w ell-characterized group of outpatients w ith schizophrenia and HCs. These chem okines inclu ded eigh t C\\ C m ot if ch em okin e ligan ds: MCP-1 ( CCL2) , MIP-1α ( CCL3) , MIP-1β ( CCL4) , Eotaxin-1 ( CCL11), MCP-4 ( CCL13), TARC (CCL17), MDC (CCL22), Eotaxin-3 (CCL26); two C\\ X\\ C m otif ligands: IL-8 ( CXCL8) an d IP-10 ( CXCL10) ; an d on e C\\ X3\\ C m otif ligand : fractalkine (CX3CL1). Our panel contained chem okines of both innate and adaptive im m unity w ith inflam m atory ( MCP-1, MIP-1α , MIP-1β, MCP-4, Eotaxin-3, IL-8, IP-10), and dual ( both inflam m atory and h om eostatic; Eotaxin-1, TARC, MDC, and fractalkine) function s ( Zlotn ik and Yoshie, 2012), and also includes ch em okines w ith know n roles in th e CNS ( MCP-1, MIP-1α , MIP-1β, Eotaxin-1, IL-8, IP-10, an d fractalkin e) (Stuart et al., 2015) . We com pared levels of each chemokine in our panel betw een people w ith schizop hrenia an d HCs. For th ose plasm a chem okines that differed betw een the tw o groups, w e examin ed w h ether the differen ces rem ain ed significant after adjusting for covariates. We also exam ined subgroups of patien ts w h o w ere m ore com parable to the HCs on body m ass index ( BMI) and sm okin g. Th e relationship of age and gender to the chem okines w as exam ined separately in th e persons w ith schizophrenia and HCs. Finally, w e created a Ch em okine In dex ( CI) based on a com bination of m arkers th at differed m ost betw een the tw o diagnostic groups, and explored clinical correlates of the Index in the tw o groups.
Experim ent al/ m at er ials and m ethods

Participants
The protocol w as approved by the University of California, San Diego ( UCSD) Hum an Research Protections Program . Participants provided w ritten in form ed consen t. These in cluded 134 outpatients w ith schizoph renia or schizoaffective disorder ( hereafter referred to collectively as schizophrenia) and 112 HCs w ith n o history of m ajor n europsychiatric disorder, recruited from the greater San Diego com m unity and enrolled in an on going study of aging in schizophrenia. Schizophrenia diagnosis w as confirm ed using the Structured Clinical Interview for the DSM-IV-TR ( SCID; First et al., 2002) . Participants w ere recruited using a structured m ulti-cohort design, w ith the tw o groups being age-m atched by decade ( 26-35, 36-45, 46-55, an d 56-65 years) . Su bject selection criteria have been previously described ( Joseph et al., 2015) .
Sociodemographic and clinical characteristics
Sociodem ograph ic characteristics ( i.e., age, education , gender, race/ ethn icity, and sm oking status) and illness-related variables ( i.e., duration of sch izoph renia and daily an tipsychotic m edication dosages ( Sw eileh et al., 2014) w ere ascertained through participant interviews and review s of records ( w ith HIPAA authorization). The Multisystem Disease Risk Score ( Carroll et al., 2015) w as calculated by sum m in g th e z-scores of h igh-den sity lipoprotein ( HDL), low -den sity lipoprotein ( LDL), triglycerides, hem oglobin A1c, glucose, in sulin , and C-reactive protein levels in blood. The Fram ingham 10-year Coronary Heart Disease Relative Risk Score ( Wilson et al., 1998) w as also com puted ( Jin et al., 2011) .
Psychosocial and cognitive assessments
Psychotic sym ptom s w ere evaluated w ith interview er-adm in istered Scales for Assessm ent of Positive Sym ptom s and Negative Sym ptom s ( SAPS and SANS, respectively) ( An dreasen, 1983 ( An dreasen, , 1984 , depression w ith th e Patien t Health Question naire -9-Item Version ( PHQ-9; Kroenke and Spitzer, 2002), health-related quality of life and functionin g w ith th e physical and m en tal health com posite scores from th e Medical Outcom es Study 36-item Short Form ( SF-36; Ware and Sherbourne, 1992) , an d m edical com orbidity w ith th e Cum ulative Illness Rating Scale (CIRS; Parm elee et al., 1995) . Current m edications, including psychotropic and anti-inflam m atory agents, w ere recorded for both groups. Assessm ent of cognitive deficits focused on executive fun ctioning (Fucetola et al., 2000; Wobrock et al., 2008) , based on three subtests from the Delis-Kaplan Executive Function System ( D-KEFS; Delis et al., 2001 ).
Chemokine assays
Fasting blood w as collected in EDTA-treated vacutainers betw een 7:00 am -12:00 pm through an intraven ous catheter inserted in to an antecubital vein using m inim al tourniquet. White blood cell count and hem atocrit w ere assessed by the UCSD Clinical Laboratory using standard procedures. Plasm a w as stored at − 80°C until assays w ere perform ed. Plasm a ch em okin e levels w ere quan tified usin g Meso Scale Discovery ( MSD) MULTI-SPOT® Assay System an d analyzed on a SEC-TOR Im ager 2400 instrum ent ( Rockville, MD, USA). Using MSD Discovery Workben ch® analysis softw are, standard curves w ere form ed by fitting ECL signal from calibrators to a 4-param eter logistic m odel w ith a 1/y 2 w eigh tin g. Sam ples w ere ru n in dup licates, u sin g V-PLEX
Hum an Biom arker pan els ( Catalog # K151A0H-2) to m easure th e chem okines. Hum an fractalkine/CX3CL1 kit ( Catalog # K151MKD-2) w as used to assay fractalkine levels. V-PLEX kits are fully validated accordin g to fit-for-purpose principles and the FDA's analytical validation guidelin es accordin g to the m anufacturer ( MSD) . Th e laboratory techn ician perform ing th e assays w as "blind" to the subject's diagnosis. Intraand inter-assay variations for chem okines w ere b10%, except the intraassay variation ( 19.4%) an d inter-assay variation ( 19.5%) for Eotaxin -3, inter-assay variation for MCP-1 ( 16.5%), and intra-assay variation for MIP-1α ( 
Statistical analysis
Values of all chem okines w ere log 10 transform ed to approxim ate a norm al distribution. Independent sam ples t-tests and Chi-square analysis w ere used to com pare continuous and discrete sam ple characteristics, respectively. Cohen 's d effect sizes w ere calculated for group differences for continuous variables, and values N0.30 w ere interpreted as greater than a sm all effect. The Success Rate Difference ( SRD) w as calculated for categorical variables as the grou p differen ce betw een the percen t of each referen ce category versus all others ( Kraem er an d Ku p fer, 2006). Th e SRD ranges from − 1 to + 1 with zero as its null value, and values N0.17 w ere interpreted as greater than a sm all effect. Chemokine data for MCP-4, MIP-1α , and TARC w ere only available in a subgroup of 155 subjects ( 84 schizophrenia and 71 HC).
Based on the literature regarding factors that m ight im pact chem okine levels or an inflam m atory state in general or in schizophrenia specifically, w e conducted a general linear m odel to exam ine the effect of group w hen age, gender, BMI, and current sm oking status w ere entered as covariates. Addition ally, because BMI and sm okin g status w ere m arkedly different betw een th e groups, w e tested w h ether sm aller subgroups of patien ts w ho resem bled HCs on BMI and sm okin g also differed from th em in chemokine levels.
To create a sin gle CI, w e first con ducted a forw ard stepw ise logistic regression w ith group as the dependent variable. The CI w as calculated for each participant as a lin ear com bination of th e in tercept and th e value of each significan t chem okin e w eighted by its param eter estim ate from the logistic regression m odel. We then explored potential associations between clinical variables and the CI by exam ining Pearson correlation s in both persons w ith sch izoph renia and HCs.
Result s
Th ere w as, as exp ected, n o sign ificant difference in age or gender betw een th e people w ith schizoph renia an d HCs ( Table 1) . Th e people w ith schizoph renia had a sligh tly low er proportion of Caucasians, low er education level, greater cigarette sm oking, h igher BMI, greater m edical com orbidity and disease risk, m ore severe depressive sym ptom s, and poorer executive functioning than HCs. Persons w ith schizophrenia w ere m ore likely to be taking psychotropic m edications an d an ti-in flam m atory agen ts. Both groups had n orm al h em atological tests an d did not have clinical evidence of fever or infection, although total w hite blood cell counts w ere som ew h at high er in th e person s w ith schizophrenia.
Levels of five CC chem okines ( MCP-1, MIP-1β, Eotaxin-1, TARC, and MDC) w ere significantly high er in the people w ith schizoph renia than in the HCs w ith m edium Cohen 's d effect sizes ( Table 2) . Effect sizes for the group difference w ere not notably reduced after adjusting for covariates (Table 3) , except in the case of TARC, where the effect size fell from d = − 0.38 to d = − 0.25. When subsets of non-sm oking schizoph ren ia ( n = 64) and HC participants ( n = 105) w ere com pared, there w ere still m edium to large effect sizes for the group differen ce for all five chem okines ( Cohen's ds from − 0.30 to − 0.50). Sim ilarly, w hen subsets of non-obese patients ( n = 60) w ere com pared to nonobese HC participants (n = 84), there w ere m edium to large group effect sizes for all chem okines, w ith som e diagn ostic effects slightly larger in this non -obese subsam ple th an in th e total sam ple th at in cluded th e full range of BMIs (Cohen's ds from − 0.43 to − 0.77).
In the above general lin ear m odel (Table 3) , w e observed m ain effects of age on MCP-1 an d Eotaxin -1 ( h igh er valu es in older participants) and m ain effects of gender on TARC and MDC ( w om en N m en for TARC; m en N women for MDC). In a separate model with age, gender, group, and all their interactions, no chem okine show ed a groupspecific gender association or any age relationships that depended on either group or gender.
To create the CI, w e entered MCP-1, MIP-1β, Eotaxin-1, and MDCin a forw ard stepw ise fash ion in to a logistic regression w ith group m em bersh ip as the dep end ent variable; the final m odel w as significan t ( χ 2 ( 2) = 20.7, p b 0.001, Nagelkerke R 2 = 0.11). MDC entered on the first step, and Eotaxin-1 en tered on th e second step. In th e final m odel, w h ich correctly identified in dividuals as m em bers of the schizoph renia vs. HC groups 64%of th e tim e, MDC ( Wald test = 9.7, p = 0.002), and Eotaxin-1 ( Wald test = 7.9, p = 0.005) levels both significan tly distinguish ed patients from HCs, and so this m odel w as used to calculate th e CI. The equ ation used for the CI calculation w as: − 10.612 + ( 0.762 × log 10 ( Eotaxin -1)) + ( 1.08 × log 10 (MDC)). As expected, the CI w as higher in persons w ith schizophrenia ( − 5.84 ± − 0.27) than in HCs (− 5.99 ± − 0.23; t = − 5.26, p b 0.0001). Schizophrenia patients with a higher CI w ere older, had longer durations of illness, and had m ore negative sym ptom s. Am ong the HCs, CI w as h igher in w om en, in dividuals w ith higher levels of subclin ical depressive sym ptom s, w orse self-rated m ental w ell-bein g, an d greater overall severity of generally m ild m edical illnesses (Table 4) .
Discussion
Plasm a levels of five CC chem okines w ere greater in schizophrenia com p ared to HC: MCP-1/CCL2, MIP-1β/CCL4, Eotaxin-1/CCL11, TARC/ CCL17, and MDC/CCL22. Eotaxin-1 and MDC w ere particularly useful in distinguishing betw een the schizophrenia and HC groups, although they should not be regarded as diagnostic m arkers. The group difference in TARC levels decreased con siderably after adjustin g for age, gen der, BMI, and sm okin g, suggesting that it w as prim arily related to dem ograph ic factors. Our findings add to studies of MCP-1 in schizophrenia that show significantly h igher levels com pared to HCs ( Beum er et al., 2012; Dim itrov et al., 2013; Dom enici et al., 2010; Reale et al., 2011; Zakharyan et al., 2012) , in contrast to other reports of no group differen ces ( Aseved o et al., 2013; Bram billa et al., 2014; Di Nicola et al., 2013; Martin ez-Cen gotitaben goa et al., 2012; Schw arz et al., 2012; Teixeira et al., 2008) . The existing literature presen ts incon sisten t findin gs for Eotaxin-1 (Asevedo et al., 2013; Bram billa et al., 2014; Dimitrov et al., 2013; Dom enici et al., 2010; Ram sey et al., 2013; Schw arz et al., 2012; Teixeira et al., 2008) and MDC (Bram billa et al., 2014; Dim itrov et al., 2013; Dom enici et al., 2010; Pedrini et al., 2014; Ram sey et al., 2013; Schw arz et al., 2012) and negative findings for MIP-1β in m ost reports (Beum er et al., 2012; Bram billa et al., 2014; Dim itrov et al., 2013; Dom enici et al., 2010; Schw arz et al., 2012) . In contrast to the C\\ C chem okin e fam ily, all C\\ X\\ C and C\\ X3\\ C chem okines exam ined in our study did not differ betw een the tw o groups. Together, our findings suggest potential differences in neuroim m une regulatory chem okines in schizophren ia, alth ough th e lin k betw een structure an d functions of chem okines in schizophrenia is unclear.
Tw o beta chem okines w ith dual hom eostatic and inflam m atory functions, MDC and Eotaxin-1, h ad particularly stron g relationships to diagnosis even after accoun tin g for in terrelation s am on g th e chem okin es. Eotaxin -1 acts prim arily on eosin ophils and is in volved in Table 3 General linear m odels testing group effect w ith age, gender, BMI, and sm oking status as covariates. aging-associated disruption s of m em ory an d h ippocam pal neurogenesis ( Villeda et al., 2011) . MDC is secreted by dendritic cells and m acroph ages, and acts on T cells, NK cells, an d m on ocytes. ( Mantovani et al., 2000) . The combination of MDC and Eotaxin-1 suggests possible dysregulation of both peripheral and neuroinflam m atory activities. Wh ile our fin din gs do n ot directly address path op h ysiology of schizophrenia, peripheral blood m arkers m ay aid in discovering reliable and practical biom arkers of im m une dysregulation in sch izophrenia. Grow in g evidence indicates that CNS im m une surveillance is critical in m aintain ing optim al brain functioning ( Kipnis et al., 2008) . Disruption of 'patrollin g' im m une cells' entry into the brain leads to im paired learning and m em ory, and behavioral abnorm alities (Schw artz and Sh echter, 2010) . Thus, dysregulation of the chemokine network m ay contribute to disease processes in schizophren ia, given th e critical role of chem okin es in in itiating m igration of im m une cells to target tissues for m ain tenance and inflam m atory functions (Foxman et al., 1997; Murphy et al., 2000a; Sprin ger, 1994) . Furth erm ore, h um an fetal astrocyte and m icroglial cells express chem okines and chem okine receptors (Rezaie et al., 2002) , and m aternal inflam m ation during gestation is lin ked to developm ent of schizophrenia (Benros et al., 2014a; Krause et al., 2010) . Recently, complem en t com ponen t 4 ( C4) protein expression abn orm alities w ere found in post-m ortem brain tissue from patients w ith sch izophrenia, consistent w ith excessive C4-m ediated syn aptic prunin g durin g m ice neurodevelopm ent (Sekar et al., 2016) . Expression of chem okines can be activated by com plem ent com ponents ( Selvan et al., 1998) , so our findings m ay reflect long-stan din g dysregulation of com plem en t fun ction.
Given that the CI was associated with illness duration and severity of negative sym ptom s, a dysregulated chem okin e "system " m ay be a feature of chronic schizophrenia w ith negative features. These associations need clarification in longitudinal studies. Noneth eless, it can be speculated that physical and m ental health could be im proved by treatm ents that regulate chem okine levels in schizophrenia patients (Keller et al., 2013 ) . The association s of CI w ith levels of subclin ical depressive sym ptom s and perception of m ental and physical health that w ere seen only in HCs m ay suggest a statistical anom aly. Unlike som e studies (Asevedo et al., 2013 ; Martin ez-Cengotitaben goa et al., 2012) we did not observe associations of cogn itive ( executive) fun ction perform an ce w ith ch em okine levels. Further w ork is needed to exam ine w hether other aspects of cogn ition m ight be related to ch em okin e elevation s in schizophrenia. A num ber of the chem okine levels w ere age-or gender-related. Identifying specific gender and/or age groups am on g schizophrenia patients that exhibit imm une dysregulation m ay be clinically valuable.
Our study h as several lim itations. This cross-sectional investigation of ch ron ic outp atien ts does not provide direct eviden ce for th e chem okin es' in volvem en t in sch izoph renia path oph ysiology. Also, there is a possibility of type I errors as w e did n ot correct for m ultiple com parison s in ou r u nivariate an alyses. Although grou p effect sizes persisted after statistically adjustin g for factors like BMI an d sm oking and exam ining non-smoking and non-obese subsam ples, both these approach es h ave th eir lim itations. Lon gitudinal studies w ould h elp in exam ining w hether changes in BMI or physical health precede changes in ch em okin es or vice versa. Fin ally, our results m ay not apply to persons w ith acute or first-episode schizophrenia or antipsychotic-naive patients.
Longitudinal and functional investigations of chem okines and their receptors w ill advan ce the field in testing whether these biomarkers predict ch an ges in clin ical severity, an d possibly contribute to pathophysiological processes in schizophrenia. Future research is needed to evaluate w hether treatm ents that n orm alize chem okin e dysregulation m ay am eliorate psych opath ology am ong ch ron ic sch izophrenia patients.
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